SG11202009982PA - Anti-inflammatory compound and preparation and use thereof - Google Patents

Anti-inflammatory compound and preparation and use thereof

Info

Publication number
SG11202009982PA
SG11202009982PA SG11202009982PA SG11202009982PA SG11202009982PA SG 11202009982P A SG11202009982P A SG 11202009982PA SG 11202009982P A SG11202009982P A SG 11202009982PA SG 11202009982P A SG11202009982P A SG 11202009982PA SG 11202009982P A SG11202009982P A SG 11202009982PA
Authority
SG
Singapore
Prior art keywords
preparation
inflammatory compound
inflammatory
compound
Prior art date
Application number
SG11202009982PA
Other languages
English (en)
Inventor
Wang Shen
Pengfei Liu
Jinping Zhu
Qiuping Luo
Pingbo Ke
Yufei Liu
Jida Shen
Original Assignee
Vivavision Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivavision Biotech Inc filed Critical Vivavision Biotech Inc
Publication of SG11202009982PA publication Critical patent/SG11202009982PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202009982PA 2018-04-26 2019-03-21 Anti-inflammatory compound and preparation and use thereof SG11202009982PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810386572.6A CN110407741B (zh) 2018-04-26 2018-04-26 一种抗炎化合物及其制备和应用
PCT/CN2019/078964 WO2019205843A1 (fr) 2018-04-26 2019-03-21 Composé anti-inflammatoire et préparation et utilisation associées

Publications (1)

Publication Number Publication Date
SG11202009982PA true SG11202009982PA (en) 2020-11-27

Family

ID=68294751

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009982PA SG11202009982PA (en) 2018-04-26 2019-03-21 Anti-inflammatory compound and preparation and use thereof

Country Status (12)

Country Link
US (1) US11440886B2 (fr)
EP (1) EP3777979B1 (fr)
JP (1) JP7364142B2 (fr)
KR (1) KR20210004982A (fr)
CN (1) CN110407741B (fr)
AU (1) AU2019258242B2 (fr)
CA (1) CA3096905C (fr)
RU (1) RU2759626C1 (fr)
SG (1) SG11202009982PA (fr)
TW (1) TWI701239B (fr)
WO (1) WO2019205843A1 (fr)
ZA (1) ZA202006347B (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228185A (ja) * 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
CA2005787A1 (fr) * 1988-12-29 1990-06-29 Masao Wada Composes de cephalosporine
GB9723078D0 (en) * 1997-10-31 1998-01-07 Cerebrus Ltd Chemical compounds
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
AU2007297221B2 (en) * 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
ES2363565T3 (es) * 2006-12-22 2011-08-09 Leo Pharma A/S Acetofenonas sustituidas útiles como inhibidores de pde4.
GB201113689D0 (en) * 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
CN102603544A (zh) * 2012-04-06 2012-07-25 南京大学 一种抗炎化合物、其制备及其用途

Also Published As

Publication number Publication date
NZ767619A (en) 2023-12-22
WO2019205843A1 (fr) 2019-10-31
US20200377460A1 (en) 2020-12-03
CA3096905A1 (fr) 2019-10-31
JP7364142B2 (ja) 2023-10-18
US11440886B2 (en) 2022-09-13
ZA202006347B (en) 2022-01-26
EP3777979A4 (fr) 2021-08-04
RU2759626C1 (ru) 2021-11-16
KR20210004982A (ko) 2021-01-13
CA3096905C (fr) 2024-01-09
CN110407741A (zh) 2019-11-05
JP2021518838A (ja) 2021-08-05
AU2019258242B2 (en) 2022-01-27
TW201945341A (zh) 2019-12-01
EP3777979B1 (fr) 2024-01-17
AU2019258242A1 (en) 2020-09-24
CN110407741B (zh) 2023-03-21
EP3777979A1 (fr) 2021-02-17
TWI701239B (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
EP3660019A4 (fr) Composé, son procédé de préparation et son utilisation
IL284514A (en) Halo-allylamine compounds and their use
IL278142A (en) Antiproliferative compounds and their uses
IL280644A (en) Magnesium serine compound and its use
IL276814A (en) Indazole-3-carboxamides converted in 5-heteroaryl and their preparation and use
IL277502A (en) Compounds and uses for them
EP3492466A4 (fr) Préparation solide orale et son utilisation
IL289416B (en) A tricyclic compound and its use
IL279483A (en) Cyanotriazole compounds and their uses
IL277749A (en) Palladianolide compounds and their use
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
ZA201905763B (en) Liposomal compositions and solid oral dosage forms comprising the same
IL276783A (en) The composition and pharmaceutical compound containing it
EP3901146A4 (fr) Composé phénylpyrrolidine et son utilisation
EP3792257A4 (fr) Composé de défactinib deutéré et son utilisation
GB201801102D0 (en) New compounds and uses
EP4051270A4 (fr) Composés de 4-amino-imidazoquinoline et utilisation de ceux-ci
ZA202006347B (en) Anti-inflammatory compound and preparation and use thereof
EP3590919A4 (fr) Composé énamine et son utilisation
IL283540A (en) Dock1 inhibitory compound and use thereof
AU2018904090A0 (en) Compounds and use thereof
EP4082614A4 (fr) Composé acylsulfamide et son utilisation pharmaceutique
EP3733660A4 (fr) Composé n-alkyl-n-cyanoalkylbenzamide et utilisation associée